Document is current
Any future updates will be listed below
-
Authors
Hilz, Max J.
Lyn, Nicole https://orcid.org/0000-0001-9707-2446
Marczykowski, Felix
Werner, Barbara
Pignot, Marc
Ponce, Elvira
Bender, Joseph
Edigkaufer, Michael
DasMahapatra, Pronabesh
-
Funding
Funding for this research was provided by:
Sanofi (NA)
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 16 June 2024
First Online: 9 July 2024
Declarations
:
: The respective company health insurance fund (BKK) was informed about the project. All required approvals were granted. All patient level data in the database were anonymized to comply with German data protection regulations.
: Patient consent statement was not required as the records in the database were anonymized.
: MJH received consultancy and speaker fees from Sanofi Genzyme and from Amicus Therapeutics, consultancy fees from Pfizer, and editor honoraria from Elsevier BV, outside of the present work. NL, EP, JB, ME, and PD are employees and may hold stock and/or stock options in Sanofi. FM is a full-time employee of Oracle Life Sciences, Munich, Germany (formerly Cerner Enviza), which received funding from Sanofi. BW is a full-time employee of Team Gesundheit GmbH. Team Gesundheit GmbH received funding from Kantar, Health Division to perform the analyses. MP is a full-time employee of ZEG Berlin GmbH, an Oracle company. ZEG Berlin GmbH received funding from Sanofi.
